Published in Arthritis Res Ther on January 01, 2014
Multiple Ascending Dose (MDX1105-01) (Anti-PDL1) | NCT00729664
Abatacept and Cyclophosphamide Combination Therapy for Lupus Nephritis (ACCESS) | NCT00774852
A Study of AMG 557 in Adults With Systemic Lupus Erythematosus | NCT00774943
Monoclonal Antibody Therapy in Treating Patients With Stage IV Melanoma | NCT00658892
Immune checkpoints and rheumatic diseases: what can cancer immunotherapy teach us? Nat Rev Rheumatol (2016) 0.78
Interleukin-4 Inhibits Regulatory T Cell Differentiation through Regulating CD103+ Dendritic Cells. Front Immunol (2017) 0.75
Anti-inflammatory effects of interleukin-23 receptor cytokine-binding homology region rebalance T cell distribution in rodent collagen-induced arthritis. Oncotarget (2016) 0.75
Metabolism-associated danger signal-induced immune response and reverse immune checkpoint-activated CD40(+) monocyte differentiation. J Hematol Oncol (2017) 0.75
High affinity anti-TIM-3 and anti-KIR monoclonal antibodies cloned from healthy human individuals. PLoS One (2017) 0.75
Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med (2010) 67.34
PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol (2008) 19.24
Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity (1999) 12.36
Psoriasis. N Engl J Med (2009) 8.80
TNF/TNFR family members in costimulation of T cell responses. Annu Rev Immunol (2005) 7.44
Replication of putative candidate-gene associations with rheumatoid arthritis in >4,000 samples from North America and Sweden: association of susceptibility with PTPN22, CTLA4, and PADI4. Am J Hum Genet (2005) 6.61
Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum (2010) 4.57
A regulatory polymorphism in PDCD1 is associated with susceptibility to systemic lupus erythematosus in humans. Nat Genet (2002) 4.03
High serum IFN-alpha activity is a heritable risk factor for systemic lupus erythematosus. Genes Immun (2007) 3.59
Molecular mechanism and function of CD40/CD40L engagement in the immune system. Immunol Rev (2009) 3.56
TL1A is a TNF-like ligand for DR3 and TR6/DcR3 and functions as a T cell costimulator. Immunity (2002) 3.46
Deficient CD4+CD25high T regulatory cell function in patients with active systemic lupus erythematosus. J Immunol (2007) 3.22
The B7 family member B7-H6 is a tumor cell ligand for the activating natural killer cell receptor NKp30 in humans. J Exp Med (2009) 3.17
4-1BB-mediated immunotherapy of rheumatoid arthritis. Nat Med (2004) 3.01
A new population of cells lacking expression of CD27 represents a notable component of the B cell memory compartment in systemic lupus erythematosus. J Immunol (2007) 2.79
Treatment of murine lupus with CTLA4Ig. Science (1994) 2.69
CTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris. J Clin Invest (1999) 2.58
Correlation between circulating CD27high plasma cells and disease activity in patients with systemic lupus erythematosus. Arthritis Rheum (2003) 2.32
The efficacy and safety of abatacept in patients with non-life-threatening manifestations of systemic lupus erythematosus: results of a twelve-month, multicenter, exploratory, phase IIb, randomized, double-blind, placebo-controlled trial. Arthritis Rheum (2010) 2.27
Evidence for impaired T cell DNA methylation in systemic lupus erythematosus and rheumatoid arthritis. Arthritis Rheum (1990) 2.27
Costimulatory molecule-targeted antibody therapy of a spontaneous autoimmune disease. Nat Med (2002) 2.23
Lymphocytes in the skin of patients with progressive systemic sclerosis. Quantification, subtyping, and clinical correlations. Arthritis Rheum (1984) 2.17
A short course of BG9588 (anti-CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis. Arthritis Rheum (2003) 2.11
Abatacept in the treatment of patients with psoriatic arthritis: results of a six-month, multicenter, randomized, double-blind, placebo-controlled, phase II trial. Arthritis Rheum (2011) 2.11
Hyperexpression of CD40 ligand by B and T cells in human lupus and its role in pathogenic autoantibody production. J Clin Invest (1996) 2.09
The ups and downs of T cell costimulation. Immunity (1994) 2.00
Rituximab in systemic lupus erythematosus: A systematic review of off-label use in 188 cases. Lupus (2009) 1.97
The global burden of rheumatoid arthritis: estimates from the global burden of disease 2010 study. Ann Rheum Dis (2014) 1.97
Cellular infiltrates in scleroderma skin. Arthritis Rheum (1977) 1.96
Increased expression of CD40 ligand on systemic lupus erythematosus lymphocytes. J Clin Invest (1996) 1.86
Sequential dermal microvascular and perivascular changes in the development of scleroderma. J Pathol (1992) 1.81
Activated renal macrophages are markers of disease onset and disease remission in lupus nephritis. J Immunol (2008) 1.79
Immunotherapy earns its spot in the ranks of cancer therapy. J Exp Med (2012) 1.71
Defects in CTLA-4 are associated with abnormal regulatory T cell function in rheumatoid arthritis. Proc Natl Acad Sci U S A (2008) 1.69
Involvement of inducible costimulator in the exaggerated memory B cell and plasma cell generation in systemic lupus erythematosus. Arthritis Rheum (2004) 1.66
Abnormal germinal center reactions in systemic lupus erythematosus demonstrated by blockade of CD154-CD40 interactions. J Clin Invest (2003) 1.63
Autoantibody induction by DNA-containing immune complexes requires HMGB1 with the TLR2/microRNA-155 pathway. J Immunol (2013) 1.61
B-cell targeted therapies in human autoimmune diseases: an updated perspective. Immunol Rev (2010) 1.60
B7 family checkpoint regulators in immune regulation and disease. Trends Immunol (2013) 1.53
CD137 costimulatory T cell receptor engagement reverses acute disease in lupus-prone NZB x NZW F1 mice. J Clin Invest (2003) 1.52
Demethylation of TNFSF7 contributes to CD70 overexpression in CD4+ T cells from patients with systemic sclerosis. Clin Immunol (2012) 1.48
Diminished peripheral blood memory B cells and accumulation of memory B cells in the salivary glands of patients with Sjögren's syndrome. Arthritis Rheum (2002) 1.47
Treatment of systemic lupus erythematosus by inhibition of T cell costimulation with anti-CD154: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum (2002) 1.39
Pathogenesis and prevention of rheumatic disease: focus on preclinical RA and SLE. Nat Rev Rheumatol (2014) 1.39
Autoantibody profiles in systemic sclerosis: predictive value for clinical evaluation and prognosis. J Dermatol (2010) 1.37
The soluble CD40 ligand sCD154 in systemic lupus erythematosus. J Clin Invest (1999) 1.33
Functional CD40 ligand is expressed by T cells in rheumatoid arthritis. J Clin Invest (1997) 1.32
Genetic aspects of Sjögren's syndrome. Arthritis Res (2002) 1.30
Cutting edge: reversal of murine lupus nephritis with CTLA4Ig and cyclophosphamide. J Immunol (2001) 1.27
Autoantibodies to T cell costimulatory molecules in systemic autoimmune diseases. J Immunol (1999) 1.26
Structure and specificity of T cell receptors expressed by potentially pathogenic anti-DNA autoantibody-inducing T cells in human lupus. J Clin Invest (1995) 1.26
A new haplotype of PDCD1 is associated with rheumatoid arthritis in Hong Kong Chinese. Arthritis Rheum (2005) 1.24
Unchecked CD70 expression on T cells lowers threshold for T cell activation in rheumatoid arthritis. J Immunol (2007) 1.22
Association of EBF1, FAM167A(C8orf13)-BLK and TNFSF4 gene variants with primary Sjögren's syndrome. Genes Immun (2010) 1.21
TL1A and DR3, a TNF family ligand-receptor pair that promotes lymphocyte costimulation, mucosal hyperplasia, and autoimmune inflammation. Immunol Rev (2011) 1.19
Development of autoimmune hepatitis-like disease and production of autoantibodies to nuclear antigens in mice lacking B and T lymphocyte attenuator. Arthritis Rheum (2008) 1.18
The role of CD40 ligand and tumor necrosis factor alpha signaling in the transgenic K/BxN mouse model of rheumatoid arthritis. Arthritis Rheum (2000) 1.17
Association of TNFSF4 (OX40L) polymorphisms with susceptibility to systemic sclerosis. Ann Rheum Dis (2009) 1.16
Autoantibodies in primary Sjögren's syndrome: new insights into mechanisms of autoantibody diversification and disease pathogenesis. Autoimmunity (2001) 1.15
CTLA-4 polymorphisms and systemic lupus erythematosus (SLE): a meta-analysis. Hum Genet (2005) 1.14
Strong and selective glomerular localization of CD134 ligand and TNF receptor-1 in proliferative lupus nephritis. J Am Soc Nephrol (2000) 1.12
B7-H1 expression on non-B and non-T cells promotes distinct effects on T- and B-cell responses in autoimmune arthritis. Eur J Immunol (2010) 1.11
Mechanism of action of combined short-term CTLA4Ig and anti-CD40 ligand in murine systemic lupus erythematosus. J Immunol (2002) 1.11
Possible function of salivary gland epithelial cells as nonprofessional antigen-presenting cells in the development of Sjögren's syndrome. J Rheumatol (2002) 1.09
Expression of B7 costimulatory molecules by salivary gland epithelial cells in patients with Sjögren's syndrome. Arthritis Rheum (1999) 1.09
Engagement of the CD137 (4-1BB) costimulatory molecule inhibits and reverses the autoimmune process in collagen-induced arthritis and establishes lasting disease resistance. Immunology (2004) 1.08
Abnormalities in peripheral B cell memory of patients with primary Sjögren's syndrome. Arthritis Rheum (2004) 1.08
Elevated levels of soluble CD40 ligand (sCD40L) in serum of patients with systemic autoimmune diseases. J Autoimmun (2006) 1.07
The programmed death 1/programmed death ligand 1 inhibitory pathway is up-regulated in rheumatoid synovium and regulates peripheral T cell responses in human and murine arthritis. Arthritis Rheum (2010) 1.06
Influence of CTLA4 haplotypes on susceptibility and some extraglandular manifestations in primary Sjögren's syndrome. Arthritis Rheum (2006) 1.06
Involvement of inducible costimulator-B7 homologous protein costimulatory pathway in murine lupus nephritis. J Immunol (2003) 1.04
A soluble form of CD137 (ILA/4-1BB), a member of the TNF receptor family, is released by activated lymphocytes and is detectable in sera of patients with rheumatoid arthritis. Eur J Immunol (1998) 1.03
Anti-programmed cell death 1 antibody reduces CD4+PD-1+ T cells and relieves the lupus-like nephritis of NZB/W F1 mice. J Immunol (2010) 1.02
CTLA-4-Ig therapy diminishes the frequency but enhances the function of Treg cells in patients with rheumatoid arthritis. J Clin Immunol (2011) 1.02
Soluble CD154 in rheumatoid arthritis: elevated plasma levels in cases with vasculitis. J Rheumatol (2001) 1.02
Antifibroblast antibodies in systemic sclerosis induce fibroblasts to produce profibrotic chemokines, with partial exploitation of toll-like receptor 4. Arthritis Rheum (2008) 1.00
Baseline numbers of circulating CD28-negative T cells may predict clinical response to abatacept in patients with rheumatoid arthritis. J Rheumatol (2011) 1.00
Increased salivary gland tissue expression of Fas, Fas ligand, cytotoxic T lymphocyte-associated antigen 4, and programmed cell death 1 in primary Sjögren's syndrome. Arthritis Rheum (2003) 0.96
Classical to current approach for treatment of psoriasis: a review. Endocr Metab Immune Disord Drug Targets (2012) 0.96
Detection of circulating soluble CD28 in patients with systemic lupus erythematosus, primary Sjögren's syndrome and systemic sclerosis. Clin Exp Immunol (2004) 0.95
Potential role of decoy B7-H4 in the pathogenesis of rheumatoid arthritis: a mouse model informed by clinical data. PLoS Med (2009) 0.94
Prolonged expression of CD154 on CD4 T cells from pediatric lupus patients correlates with increased CD154 transcription, increased nuclear factor of activated T cell activity, and glomerulonephritis. Arthritis Rheum (2010) 0.94
CD134 as target for specific drug delivery to auto-aggressive CD4+ T cells in adjuvant arthritis. Arthritis Res Ther (2005) 0.92
Local delivery of AAV2-CTLA4IgG decreases sialadenitis and improves gland function in the C57BL/6.NOD-Aec1Aec2 mouse model of Sjögren's syndrome. Arthritis Res Ther (2012) 0.92
Distribution and clinical significance of blood dendritic cells in children with juvenile idiopathic arthritis. Ann Rheum Dis (2007) 0.92
Study of association of CD40-CD154 gene polymorphisms with disease susceptibility and cardiovascular risk in Spanish rheumatoid arthritis patients. PLoS One (2012) 0.91
Herpesvirus entry mediator-Ig treatment during immunization aggravates rheumatoid arthritis in the collagen-induced arthritis model. J Immunol (2009) 0.91
Blockade of programmed death-1 in young (New Zealand black x New Zealand white)F1 mice promotes the activity of suppressive CD8+ T cells that protect from lupus-like disease. J Immunol (2010) 0.91
CD134 expression on CD4+ T cells is associated with nephritis and disease activity in patients with systemic lupus erythematosus. Clin Exp Immunol (2006) 0.91
Distinct mechanisms of action of anti-CD154 in early versus late treatment of murine lupus nephritis. Arthritis Rheum (2003) 0.90
Increased expression of soluble inducible costimulator ligand (ICOSL) in patients with systemic lupus erythematosus. Lupus (2009) 0.90
CD40L contributes to angiotensin II-induced pro-thrombotic state, vascular inflammation, oxidative stress and endothelial dysfunction. Basic Res Cardiol (2013) 0.90
Targeting the CD134-CD134L interaction using anti-CD134 and/or rhCD134 fusion protein as a possible strategy to prevent lupus nephritis. Rheumatol Int (2008) 0.89
Blocking of CD27-CD70 pathway by anti-CD70 antibody ameliorates joint disease in murine collagen-induced arthritis. J Immunol (2009) 0.89
DNA demethylation of CD40l in CD4+ T cells from women with systemic sclerosis: a possible explanation for female susceptibility. Arthritis Rheum (2012) 0.88
CD40L demethylation in CD4(+) T cells from women with rheumatoid arthritis. Clin Immunol (2012) 0.88
RNAi-mediated CD40-CD154 interruption promotes tolerance in autoimmune arthritis. Arthritis Res Ther (2010) 0.88
CTLA-4 +49A/G and CT60 gene polymorphisms in primary Sjögren syndrome. Arthritis Res Ther (2007) 0.88
All-trans retinoic acid mediates enhanced T reg cell growth, differentiation, and gut homing in the face of high levels of co-stimulation. J Exp Med (2007) 5.96
Mast cells are essential intermediaries in regulatory T-cell tolerance. Nature (2006) 5.49
Dendritic cells permit immune invasion of the CNS in an animal model of multiple sclerosis. Nat Med (2005) 4.67
BCMA is essential for the survival of long-lived bone marrow plasma cells. J Exp Med (2004) 4.41
Experimental autoimmune encephalitis and inflammation in the absence of interleukin-12. J Clin Invest (2002) 4.04
Cutting edge: contact-mediated suppression by CD4+CD25+ regulatory cells involves a granzyme B-dependent, perforin-independent mechanism. J Immunol (2005) 3.95
Molecular mechanism and function of CD40/CD40L engagement in the immune system. Immunol Rev (2009) 3.56
CD40/CD154 interactions at the interface of tolerance and immunity. Annu Rev Immunol (2004) 3.36
Combined TLR and CD40 triggering induces potent CD8+ T cell expansion with variable dependence on type I IFN. J Exp Med (2004) 2.89
IL-9 as a mediator of Th17-driven inflammatory disease. J Exp Med (2009) 2.78
Programmed death 1 ligand signaling regulates the generation of adaptive Foxp3+CD4+ regulatory T cells. Proc Natl Acad Sci U S A (2008) 2.73
Cutting edge: the dependence of plasma cells and independence of memory B cells on BAFF and APRIL. J Immunol (2008) 2.38
A critical role for the programmed death ligand 1 in fetomaternal tolerance. J Exp Med (2005) 2.13
Clinical and immunologic effects of intranodal autologous tumor lysate-dendritic cell vaccine with Aldesleukin (Interleukin 2) and IFN-{alpha}2a therapy in metastatic renal cell carcinoma patients. Clin Cancer Res (2009) 1.94
Cellular sources and immune functions of interleukin-9. Nat Rev Immunol (2010) 1.92
The impact of T helper and T regulatory cells on the regulation of anti-double-stranded DNA B cells. Immunity (2002) 1.89
Platelet CD40L mediates thrombotic and inflammatory processes in atherosclerosis. Blood (2010) 1.86
VISTA, a novel mouse Ig superfamily ligand that negatively regulates T cell responses. J Exp Med (2011) 1.77
Distinct cell types control lymphoid subset development by means of IL-15 and IL-15 receptor alpha expression. Proc Natl Acad Sci U S A (2004) 1.68
Deficient CD40-TRAF6 signaling in leukocytes prevents atherosclerosis by skewing the immune response toward an antiinflammatory profile. J Exp Med (2010) 1.68
Short-circuiting long-lived humoral immunity by the heightened engagement of CD40. J Clin Invest (2002) 1.67
Short-lived and long-lived bone marrow plasma cells are derived from a novel precursor population. J Exp Med (2002) 1.63
Retinoic acid can directly promote TGF-beta-mediated Foxp3(+) Treg cell conversion of naive T cells. Immunity (2009) 1.62
The CD40-TRAF6 axis controls affinity maturation and the generation of long-lived plasma cells. Nat Immunol (2002) 1.59
Mechanisms of donor-specific transfusion tolerance: preemptive induction of clonal T-cell exhaustion via indirect presentation. Blood (2003) 1.57
B7 family checkpoint regulators in immune regulation and disease. Trends Immunol (2013) 1.53
IL-23 produced by CNS-resident cells controls T cell encephalitogenicity during the effector phase of experimental autoimmune encephalomyelitis. J Clin Invest (2003) 1.50
Strategies for selective priming of memory B cells. Immunol Lett (2007) 1.47
Enhanced efficacy and reduced toxicity of multifactorial adjuvants compared with unitary adjuvants as cancer vaccines. Blood (2008) 1.43
A retinoic acid-dependent checkpoint in the development of CD4+ T cell-mediated immunity. J Exp Med (2011) 1.41
When should a rheumatologist suspect a mitochondrial myopathy? Arthritis Care Res (Hoboken) (2011) 1.39
The immortality of humoral immunity. Immunol Rev (2010) 1.33
The CD40-TRAF6 axis is the key regulator of the CD40/CD40L system in neointima formation and arterial remodeling. Blood (2008) 1.29
Distinction of the memory B cell response to cognate antigen versus bystander inflammatory signals. J Exp Med (2009) 1.25
Analysis of the underlying cellular mechanisms of anti-CD154-induced graft tolerance: the interplay of clonal anergy and immune regulation. J Immunol (2005) 1.22
CD154 on the surface of CD4+CD25+ regulatory T cells contributes to skin transplant tolerance. Transplantation (2003) 1.19
A genetic lesion that arrests plasma cell homing to the bone marrow. Proc Natl Acad Sci U S A (2003) 1.16
Transplantation survival is maintained by granzyme B+ regulatory cells and adaptive regulatory T cells. J Immunol (2008) 1.14
The rise and fall of long-lived humoral immunity: terminal differentiation of plasma cells in health and disease. Immunol Rev (2003) 1.13
The diaphragms of fenestrated endothelia: gatekeepers of vascular permeability and blood composition. Dev Cell (2012) 1.13
Affinity of antigen encounter and other early B-cell signals determine B-cell fate. Curr Opin Immunol (2007) 1.11
A retinoic acid--rich tumor microenvironment provides clonal survival cues for tumor-specific CD8(+) T cells. Cancer Res (2012) 1.09
Retinoic acid in the immune system. Ann N Y Acad Sci (2008) 1.09
VISTA Regulates the Development of Protective Antitumor Immunity. Cancer Res (2014) 1.09
Dendritic cells require the NF-kappaB2 pathway for cross-presentation of soluble antigens. J Immunol (2008) 1.08
Characterization of (4-hydroxy-3-nitrophenyl)acetyl (NP)-specific germinal center B cells and antigen-binding B220- cells after primary NP challenge in mice. J Immunol (2006) 1.07
Tryptophan hydroxylase-1 regulates immune tolerance and inflammation. J Exp Med (2012) 1.06
Imprinting the fate of antigen-reactive B cells through the affinity of the B cell receptor. J Immunol (2006) 1.05
A randomized trial of ex vivo CD40L activation of a dendritic cell vaccine in colorectal cancer patients: tumor-specific immune responses are associated with improved survival. Clin Cancer Res (2010) 1.05
The balance between donor T cell anergy and suppression versus lethal graft-versus-host disease is determined by host conditioning. J Immunol (2002) 1.04
Role of the Campylobacter jejuni Cj1461 DNA methyltransferase in regulating virulence characteristics. J Bacteriol (2008) 1.02
Mast cells condition dendritic cells to mediate allograft tolerance. Immunity (2011) 1.02
Evaluation of procedures for outer membrane isolation from Campylobacter jejuni. Microbiology (2009) 1.01
Interleukin-9 as a T helper type 17 cytokine. Immunology (2010) 1.01
Cellular responses to murine CD40 in a mouse B cell line may be TRAF dependent or independent. Eur J Immunol (2002) 1.00
Polynucleotide phosphorylase has an impact on cell biology of Campylobacter jejuni. Front Cell Infect Microbiol (2012) 0.99
The roles of mast cells in anticancer immunity. Cancer Immunol Immunother (2012) 0.98
In vivo cyclophosphamide and IL-2 treatment impedes self-antigen-induced effector CD4 cell tolerization: implications for adoptive immunotherapy. J Immunol (2004) 0.98
Combined effects of calcineurin inhibitors or sirolimus with anti-CD40L mAb on alloengraftment under nonmyeloablative conditions. Blood (2002) 0.97
A temperature-regulated Campylobacter jejuni gluconate dehydrogenase is involved in respiration-dependent energy conservation and chicken colonization. Mol Microbiol (2008) 0.97
Polynucleotide phosphorylase protects Escherichia coli against oxidative stress. Biochemistry (2009) 0.95
Retinoic acid: a key player in immunity. Biofactors (2010) 0.95
Long-term survival of Campylobacter jejuni at low temperatures is dependent on polynucleotide phosphorylase activity. Appl Environ Microbiol (2009) 0.95
Developing a rational tumor vaccine therapy for renal cell carcinoma: immune yin and yang. Clin Cancer Res (2007) 0.93
Distinct mechanisms of action of anti-CD154 in early versus late treatment of murine lupus nephritis. Arthritis Rheum (2003) 0.90
Augmentation of regulatory B cell activity in experimental allergic encephalomyelitis by glatiramer acetate. J Neuroimmunol (2010) 0.89
Mast cells impair the development of protective anti-tumor immunity. Cancer Immunol Immunother (2012) 0.88
Critical role for all-trans retinoic acid for optimal effector and effector memory CD8 T cell differentiation. J Immunol (2013) 0.88
Mast cell mediators in tolerance. Curr Opin Immunol (2010) 0.86
Inhibiting retinoic acid signaling ameliorates graft-versus-host disease by modifying T-cell differentiation and intestinal migration. Blood (2013) 0.85
CD40 signaling through a newly identified tumor necrosis factor receptor-associated factor 2 (TRAF2) binding site. J Biol Chem (2003) 0.85
The in vivo function of a noncanonical TRAF2-binding domain in the C-terminus of CD40 in driving B-cell growth and differentiation. Blood (2007) 0.84
Interleukin-9 and T cell subsets. Cell Cycle (2009) 0.83
CD40-mediated up-regulation of Toll-like receptor 4-MD2 complex on the surface of murine dendritic cells. J Leukoc Biol (2003) 0.81
CD40/CD154 ligation is required for the development of acute ileitis following oral infection with an intracellular pathogen in mice. Gastroenterology (2002) 0.81
All-trans retinoic acid-induced focal myositis, synovitis, and mononeuritis. J Clin Rheumatol (2009) 0.80
The enigmatic role of mast cells in dominant tolerance. Curr Opin Organ Transplant (2009) 0.80
Dissecting the role of retinoic acid receptor isoforms in the CD8 response to infection. J Immunol (2014) 0.79
Cytokine working group study of lymphodepleting chemotherapy, interleukin-2, and granulocyte-macrophage colony-stimulating factor in patients with metastatic melanoma: clinical outcomes and peripheral-blood cell recovery. J Clin Oncol (2010) 0.79
Distinctive maturation of in vitro versus in vivo anti-CD40 mAb-matured dendritic cells in mice. J Immunother (2003) 0.77
The selective triggering of CD40 on keratinocytes in vivo enhances cell-mediated immunity. Eur J Immunol (2002) 0.77
B cell survival: an unexpected mechanism of lymphocyte vitality. Immunol Cell Biol (2008) 0.76
Pillars Article: A 39-kDa Protein on Activated Helper T Cells Binds CD40 and Transduces the Signal for Cognate Activation of B Cells. Proc. Natl. Acad. Sci. 1992. 89: 6550-6554. J Immunol (2016) 0.75
Rheumatologic manifestations in myelodysplastic syndrome. J Clin Rheumatol (2012) 0.75
Studying mast cells in peripheral tolerance by using a skin transplantation model. Methods Mol Biol (2015) 0.75
Fatal aortic dissection due to a fulminant variety of isolated aortitis. J Clin Rheumatol (2009) 0.75
Autoimmune diseases have been the focus of intense research efforts. Curr Opin Immunol (2011) 0.75